Current advances in biomarkers for targeted therapy in triple-negative breast cancer

References

• SiegelRMaJZouZJemalACancer statistics, 2014CA Cancer J Clin201464192924399786
   PubMed Web of Science ®Google Scholar
• PodoFBuydensLMDeganiHFEMME Consortium. Triple-negative breast cancer: present challenges and new perspectivesMol Oncol20104320922920537966
   PubMed Web of Science ®Google Scholar
• BenderRJMac GabhannFExpression of VEGF and semaphorin genes define subgroups of triple negative breast cancerPLoS One201385e6178823667446
   PubMed Web of Science ®Google Scholar
• Van PoznakCSomerfieldMRBastRCUse of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American society of clinical oncology clinical practice guidelineJ Oncol Pract2015332426952704
   Google Scholar
• PerouCMMolecular stratification of triple-negative breast cancersOncologist201116Suppl 16170
   PubMed Web of Science ®Google Scholar
• de GramontAWatsonSEllisLMRodónJTaberneroJde GramontAHamiltonSRPragmatic issues in biomarker evaluation for targeted therapies in cancerNat Rev Clin Oncol201512419721225421275
   PubMed Web of Science ®Google Scholar
• LipsEHMichautM3HoogstraatMCenter for Personalized Cancer Treatment. Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy responseBreast Cancer Res201517113426433948
   PubMed Web of Science ®Google Scholar
• DufourRDaumarPMounetouEBCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to OlaparibSci Rep201551267026234720
   PubMed Web of Science ®Google Scholar
• ChenDRLuDYLinHYYehWLMesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancerBiomed Res Int2014201453216125140317
   PubMed Web of Science ®Google Scholar
• KashiwagiSYashiroMTakashimaTc-Kit expression as a prognostic molecular marker in patients with basal-like breast cancerBr J Surg2013100449049623319435
   PubMed Web of Science ®Google Scholar
• MoWLiuQ1LinCCmTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancerClin Cancer Res20162271699171226546619
   PubMed Web of Science ®Google Scholar
• JudesGRifaïKDauresMDuboisLBignonYJPenault-LlorcaFBernard-GallonDHigh-throughput «Omics» technologies: New tools for the study of triple-negative breast cancerCancer Lett2016 pii: S0304–S3835(16)30137–30139
   Web of Science ®Google Scholar
• ClaudinoWMQuattroneABiganzoliLPestrinMBertiniIDi LeoAMetabolomics: available results, current research projects in breast cancer, and future applicationsJ Clin Oncol200725192840284617502626
   PubMed Web of Science ®Google Scholar
• GastMCSchellensJHBeijnenJHClinical proteomics in breast cancer: a reviewBreast Cancer Res Treat20091161172919082706
   PubMed Web of Science ®Google Scholar
• MoestueSADamCGGoradSSMetabolic biomarkers for response to PI3K inhibition in basal-like breast cancerBreast Cancer Res2013151R1623448424
   PubMed Web of Science ®Google Scholar
• ChenSMGuoCLShiJJHSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancerInt J Cancer2014135102462247424706460
   PubMed Web of Science ®Google Scholar
• LimSOLiCWXiaWEGFR Signaling enhances aerobic glycolysis in triple-negative breast cancer cells to promote tumor growth and immune escapeCancer Res20167651284129626759242
   PubMed Web of Science ®Google Scholar
• ZhuXShanLWangFHypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancerBreast Cancer Res Treat2015150347948625783183
   PubMed Web of Science ®Google Scholar
• YoungSPilarskiRTDonenbergTThe prevalence of BRCA1 mutations among young women with triple-negative breast cancerBMC Cancer200998619298662
   PubMed Web of Science ®Google Scholar
• NandaRSchummLPCummingsSGenetic testing in an ethnically diverse cohort of high-risk women: A comparative analysis of brca1 and brca2 mutations in american families of european and african ancestryJAMA2005294151925193316234499
   PubMed Web of Science ®Google Scholar
• ChenXSYuanYGarfieldDHWuJYHuangOShenKWBoth carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysisPLoS One201499e10840525247558
   PubMed Web of Science ®Google Scholar
• EggerGLiangGAparicioAJonesPAEpigenetics in human disease and prospects for epigenetic therapyNature2004429699045746315164071
   PubMed Web of Science ®Google Scholar
• JaenischRBirdAEpigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signalsNat Genet200333Suppl24525412610534
   PubMed Web of Science ®Google Scholar
• HsuNCHuangYFYokoyamaKKChuPYChenFMHouMFMethylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancerPLoS One201382e5625623405268
   PubMed Web of Science ®Google Scholar
• ToffoliSBarIAbdel-SaterFIdentification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancerBreast Cancer Res201416646625416589
   PubMed Web of Science ®Google Scholar
• XuYDiaoLChenYPromoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapyAnn Oncol20132461498150523406733
   PubMed Web of Science ®Google Scholar
• SainiKSSainiMLMarbaixEBiobanking in the era of precision oncologyIndian J Med Paediatr Oncol20153611225810568
   PubMedGoogle Scholar
• WagnerPDSrivastavaSNew paradigms in translational science research in cancer biomarkersTransl Res2012159434335322424436
   PubMed Web of Science ®Google Scholar
• HouthuijzenJMDaenenLGMRoodhartJMLVoestEEThe role of mesenchymal stem cells in anti-cancer drug resistance and tumour progressionBr J Cancer2012106121901190622596239
   PubMed Web of Science ®Google Scholar
• XinYLiJWuJPharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumorsClin Cancer Res201218216040604822962439
   PubMed Web of Science ®Google Scholar
• AchenMGStackerSAThe vascular endothelial growth factor family; proteins which guide the development of the vasculatureInt J Exp Pathol199879525526510193309
   PubMed Web of Science ®Google Scholar
• NishidaNYanoHNishidaTKamuraTKojiroMAngiogenesis in cancerVasc Health Risk Manag20062321321917326328
   PubMedGoogle Scholar
• NingQLiuCHouLVascular endothelial growth factor receptor-1 activation promotes migration and invasion of breast cancer cells through epithelial-mesenchymal transitionPLoS One201386e6521723776453
   PubMed Web of Science ®Google Scholar
• RobertiMPArriagaJMBianchiniMProtein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude miceCancer Biol Ther201213111123114022825326
   PubMed Web of Science ®Google Scholar
• BahhnassyAMohanadMShaarawySTransforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancerMol Med Rep201512185186425824321
   PubMed Web of Science ®Google Scholar
• GhoshSSullivanCAZerkowskiMPHigh levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancerHuman Pathol200839121835184318715621
   PubMed Web of Science ®Google Scholar
• TahaFMZeeneldinAAHelalAMPrognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancerClin Biochem20094213–141420142619576877
   PubMed Web of Science ®Google Scholar
• BearHDTangGRastogiPBevacizumab added to neoadjuvant chemotherapy for breast cancerN Engl J Med2012366431032022276821
   PubMed Web of Science ®Google Scholar
• TolaneySMBoucherYDudaDGRole of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patientsProc Natl Acad Sci U S A201511246143251433026578779
   PubMed Web of Science ®Google Scholar
• AndréFZielinskiCCOptimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agentsAnn Oncol201223Suppl 6vi46vi5123012302
   PubMed Web of Science ®Google Scholar
• NatarajanKXieYBaerMRRossDDRole of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceBiochem Pharmacol20128381084110322248732
   PubMed Web of Science ®Google Scholar
• FinnRSBengalaCIbrahimNDasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 studyClin Cancer Res201117216905691322028489
   PubMed Web of Science ®Google Scholar
• Komeili-MovahhedTFouladdelSBarzegarEPI3K/Akt inhibition and down-regulation of BCRP re-sensitize MCF7 breast cancer cell line to mitoxantrone chemotherapyIran J Basic Med Sci201518547247726124933
   PubMed Web of Science ®Google Scholar
• VillareteLHRemickDGTranscriptional and post-transcriptional regulation of interleukin-8Am J Pathol19961495168516938909257
   PubMed Web of Science ®Google Scholar
• MonteroJCEsparis-OgandoARe-LouhauMFActive kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancerOncogene201433214815623246963
   PubMed Web of Science ®Google Scholar
• BaxiSMTanWMurphySTSmealTYinMJTargeting 3-phos-phoinoside - dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cellsPLoS One2012710e4840223119004
   PubMed Web of Science ®Google Scholar
• EdlingCEHallbergBc-Kit – a hematopoietic cell essential receptor tyrosine kinaseInt J Biochem Cell Biol200739111995199817350321
   PubMed Web of Science ®Google Scholar
• NogiHKobayashiTSuzukiMEGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancerOncol Rep200921241341719148516
   PubMed Web of Science ®Google Scholar
• CheangMCVoducDBajdikCBasal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotypeClin Cancer Res20081451368137618316557
   PubMed Web of Science ®Google Scholar
• CareyLARugoHSMarcomPKTBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancerJ Clin Oncol201230212615262322665533
   PubMed Web of Science ®Google Scholar
• ToyamaTYamashitaHKondoNFrequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancersBMC Cancer2008830918950515
   PubMed Web of Science ®Google Scholar
• TengYHTanWJThikeAAMutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapyBreast Cancer Res2011132R3521457545
   PubMed Web of Science ®Google Scholar
• JacotWLopez-CrapezEThezenasSLack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profilesBreast Cancer Res201113619
   Web of Science ®Google Scholar
• MarzecKABaxterRCMartinJLTargeting insulin-like growth factor binding protein-3 signaling in triple-negative breast cancerBioMed Res Int2015201563852626221601
   PubMed Web of Science ®Google Scholar
• ZhaJLacknerMRTargeting the insulin-like growth factor receptor-1R pathway for cancer therapyClin Cancer Res20101692512251720388853
   PubMed Web of Science ®Google Scholar
• WangCGaoCMengKQiaoHWangYHuman adipocytes stimulate invasion of breast cancer MCF-7 cells by secreting IGFBP-2PLoS One2015103e011934825747684
   PubMed Web of Science ®Google Scholar
• RoseDPHaffnerSMBaillargeonJAdiposity, the metabolic syndrome, and breast cancer in African-American and white American womenEndocr Rev200728776377717981890
   PubMed Web of Science ®Google Scholar
• MountziosGAivaziDKostopoulosIDifferential expression of the insulin-like growth factor receptor among early breast cancer subtypesPLoS One201493e9140724637962
   PubMed Web of Science ®Google Scholar
• SohnJDoKALiuSFunctional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapyAnn Oncol201324102522252623925999
   PubMed Web of Science ®Google Scholar
• HernandezBYWilkensLRLe MarchandLHorioDChongCDLooLWDifferences in IGF-axis protein expression and survival among multiethnic breast cancer patientsCancer Med20154335436225619494
   PubMed Web of Science ®Google Scholar
• MartinJLde SilvaHCLinMZScottCDBaxterRCInhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockadeMol Cancer Ther201413231632824337110
   PubMed Web of Science ®Google Scholar
• LiJSongZWangYOverexpression of SphK1 enhances cell proliferation and invasion in triple-negative breast cancer via the PI3K/AKT signaling pathwayTumour Biol2016378105871059326857281
   PubMedGoogle Scholar
• ThikeAACheokPYJara-LazaroARTanBTanPTanPHTriple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancerMod Pathol201023112313319855377
   PubMed Web of Science ®Google Scholar
• ZhuYWangYGuanBC-kit and PDGFRA gene mutations in triplenegative breast cancerInt J Clin Exp Pathol2014774280428525120810
   PubMed Web of Science ®Google Scholar
• JohanssonIAaltonenKEEbbessonAIncreased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosisGenes Chromosomes Cancer201251437538322170730
   PubMed Web of Science ®Google Scholar
• JanssonSBendahl PäOGrabauDAThe three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancerPLoS One201497e10217625025175
   PubMed Web of Science ®Google Scholar
• CuriglianoGPivotXCortesJRandomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancerBreast201322565065623958375
   PubMed Web of Science ®Google Scholar
• OrganSLTsaoMSAn overview of the c-MET signaling pathwayTher Adv Med Oncol201131 SupplS7S1922128289
   PubMedGoogle Scholar
• HsuYHYaoJChanLCDefinition of PKC-alpha, CDK6, and MET as therapeutic targets in triple-negative breast cancerCancer Res201474174822483524970481
   PubMed Web of Science ®Google Scholar
• Gonzalez-AnguloAMChenHKaruturiMSFrequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancerCancer2013119171522736407
   PubMed Web of Science ®Google Scholar
• YiYWYouKBaeEJKwakSJSeongYSBaeIDual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6Int J Oncol201547112213225955731
   PubMed Web of Science ®Google Scholar
• DierasVCamponeMYardleyDARandomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancerAnn Oncol20152691904191026202594
   PubMed Web of Science ®Google Scholar
• TolaneySMTanSGuoHPhase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancerInvest New Drugs20153351108111426123926
   PubMed Web of Science ®Google Scholar
• YanSJiaoXZouHLiKPrognostic significance of c-Met in breast cancer: a meta-analysis of 6010 casesDiagn Pathol2015106226047809
   PubMed Web of Science ®Google Scholar
• SolimanHKhalilFAntoniaSPD-L1 expression is increased in a subset of basal type breast cancer cellsPLoS One201492e8855724551119
   PubMed Web of Science ®Google Scholar
• MuenstSSchaerliARGaoFExpression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancerBreast Cancer Res Treat20141461152424842267
   PubMed Web of Science ®Google Scholar
• GatalicaZSnyderCManeyTProgrammed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer typeCancer Epidemiol Biomarkers Prev201423122965297025392179
   PubMed Web of Science ®Google Scholar
• MittendorfEAPhilipsAVMeric-BernstamFPD-L1 Expression in triple negative breast cancerCancer Immunol Res20142436137024764583
   PubMed Web of Science ®Google Scholar
• NandaRChowLQDeesECPembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 studyJ Clin Oncol201634212460246727138582
   PubMed Web of Science ®Google Scholar
• HollanderMCBlumenthalGMDennisPAPTEN loss in the continuum of common cancers, rare syndromes and mouse modelsNat Rev Cancer201111428930121430697
   PubMed Web of Science ®Google Scholar
• KeirMEButteMJFreemanGJSharpeAHPD-1 and its ligands in tolerance and immunityAnnu Rev Immunol20082667770418173375
   PubMed Web of Science ®Google Scholar
• PandeMBondyMLDoKAAssociation between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survivalBreast Cancer Res Treat2014147238138725108739
   PubMed Web of Science ®Google Scholar
• MillerTWBalkoJMArteagaCLPhosphatidylinositol 3-kinase and antiestrogen resistance in breast cancerJ Clin Oncol201129334452446122010023
   PubMed Web of Science ®Google Scholar
• TaneiTMorimotoKShimazuKAssociation of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancersClin Cancer Res200915124234424119509181
   PubMed Web of Science ®Google Scholar
• PowellEShaoJYuanYp53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancerBreast Cancer Res20161811326818199
   PubMed Web of Science ®Google Scholar
• ShahSPRothAGoyaRThe clonal and mutational evolution spectrum of primary triple negative breast cancersNature2012486740339539922495314
   PubMed Web of Science ®Google Scholar
• CantleyLCThe Phosphoinositide 3-kinase pathwayScience200229655731655165712040186
   PubMed Web of Science ®Google Scholar
• YamnikRLDigilovaADavisDCBrodtZNMurphyCJHolzMKS6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferationJ Biol Chem2009284106361636919112174
   PubMed Web of Science ®Google Scholar
• GingrasACGygiSPRaughtBRegulation of 4E-BP1 phosphorylation: a novel two-step mechanismGenes Dev199913111422143710364159
   PubMed Web of Science ®Google Scholar
• BraunsteinSKarpishevaKPolaCA hypoxia-controlled capdependent to cap-independent translation switch in breast cancerMol Cell200728350151217996713
   PubMed Web of Science ®Google Scholar
• ZhouXTanMStone HawthorneVActivation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancersClin Cancer Res200410206779678815501954
   PubMed Web of Science ®Google Scholar
• ShrivastavaSKulkarniPThummuriDPiperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cellsApoptosis20141971148116424729100
   PubMed Web of Science ®Google Scholar
• DePSunYCarlsonJHFriedmanLSLeyland-JonesBRDeyNDoubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-nessNeoplasia2014161437224563619
   PubMed Web of Science ®Google Scholar
• WalshSFlanaganLQuinnCmTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumorsBreast201221217818221963359
   PubMed Web of Science ®Google Scholar
• AlabertCChromatin dynamics during DNA replication and uncharacterized replication factors determined by nascent chromatin capture (NCC) proteomicsNat Cell Biol201416328129324561620
   PubMed Web of Science ®Google Scholar
• AlagozMKatsukiYOgiwaraHSETDB1, HP1 and SUV39 promote repositioning of 53BP1 to extend resection during homologous recombination in G2 cellsNucleic Acids Research201543167931794426206670
   PubMed Web of Science ®Google Scholar
• ChoiJDParkMALeeJSSuppression and recovery of BRCA1-mediated transcription by HP1gamma via modulation of promoter occupancyNucleic Acids Res20124022113211133823074186
   PubMed Web of Science ®Google Scholar
• TanMHMesterJLNgeowJRybickiLAOrloffMSEngCLifetime cancer risks in individuals with germline PTEN mutationsClin Cancer Res201218240040722252256
   PubMed Web of Science ®Google Scholar
• HicksCKumarRPannutiAAn integrative genomics approach for associating GWAS information with triple-negative breast cancerCancer Inform20131212023423317
   PubMedGoogle Scholar
• BegSSirajAKPrabhakaranSLoss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancerBreast Cancer Res Treat2015151354155325981902
   PubMed Web of Science ®Google Scholar
• GrindeMTSkrboNMoestueSAInterplay of choline metabolites and genes in patient-derived breast cancer xenograftsBreast Cancer Res2014161R524447408
   PubMed Web of Science ®Google Scholar
• TomitaHTanakaKTanakaTHaraAAldehyde dehydrogenase 1A1 in stem cells and cancerOncotarget2016710110181103226783961
   PubMedGoogle Scholar
• KimSJKimYSJangEDSeoKJKimJSPrognostic impact and clinicopathological correlation of CD133 and ALDH1 expression in invasive breast cancerJ Breast Cancer201518434735526770241
   PubMed Web of Science ®Google Scholar
• MarcatoPDeanCAPanDAldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasisStem Cells2011291324521280157
   PubMed Web of Science ®Google Scholar
• OhiYUmekitaYYoshiokaTAldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancerHistopathology201159477678022014057
   PubMed Web of Science ®Google Scholar
• ProctorEKidwellKMJiaggeECharacterizing breast cancer in a population with increased prevalence of triple-negative breast cancer: androgen receptor and ALDH1 expression in ghanaian womenAnn Surg Oncol201522123831383525743329
   PubMed Web of Science ®Google Scholar
• LehmannBDBauerJAChenXSandersMEChakravarthyABShyrYPietenpolJAIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJ Clin Invest201112172750276721633166
   PubMed Web of Science ®Google Scholar
• ShiovitzSKordeLAGenetics of breast cancer: a topic in evolutionAnn Oncol20152671291129925605744
   PubMed Web of Science ®Google Scholar
• UrruticoecheaASmithIEDowsettMProliferation marker Ki-67 in early breast cancerJ Clin Oncol200523287212722016192605
   PubMed Web of Science ®Google Scholar
• TungNLinNUKiddJFrequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancerJ Clin Oncol201634131460146826976419
   PubMed Web of Science ®Google Scholar
• TurnerNTuttAAshworthAHallmarks of ‘BRCAness’ in sporadic cancersNat Rev Cancer200441081481915510162
   PubMed Web of Science ®Google Scholar
• LeeLJAlexanderBSchnittSJComanderAGallagherBGarberJETungNClinical outcome of triple negative breast cancer in BRCA1 mutation carriers and non-carriersCancer2011117143093310021264845
   PubMed Web of Science ®Google Scholar
• DentRTrudeauMPritchardKITriple-negative breast cancer: clinical features and patterns of recurrenceClin Cancer Res200713154429443417671126
   PubMed Web of Science ®Google Scholar
• FoulkesWDMetcalfeKHannaWDisruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinomaCancer20039881569157714534871
   PubMed Web of Science ®Google Scholar
• AndersonDEFamilial versus sporadic breast cancerCancer1992706 Suppl174017461516029
   PubMed Web of Science ®Google Scholar
• AtchleyDPAlbarracinCTLopezAClinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancerJ Clin Oncol200826264282428818779615
   PubMed Web of Science ®Google Scholar
• MusolinoABellaMABortesiBBRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based studyBreast200716328029217257844
   PubMed Web of Science ®Google Scholar
• StefanssonOAJonassonJGJohannssonOTOlafsdottirKSteinarsdottirMValgeirsdottirSEyfjordJEGenomic profiling of breast tumours in relation to BRCA abnormalities and phenotypesBreast Cancer Res2009114R4719589159
   PubMed Web of Science ®Google Scholar
• ZugazagoitiaJPérez-SeguraPManzanoALimited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancersBreast Cancer Res Treat2014148241542125342642
   PubMed Web of Science ®Google Scholar
• StefanssonOAJonassonJGOlafsdottirKCpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancerEpigenetics20116563864921593597
   PubMed Web of Science ®Google Scholar
• BranhamMTMarzeseDMLauritoSRMethylation profile of triple-negative breast carcinomasOncogenesis201217e1723552734
   PubMed Web of Science ®Google Scholar
• FoedermayrMSebestaMRudasMBRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapyCancer Chemother Pharmacol201473477177824526178
   PubMed Web of Science ®Google Scholar
• Mitre-AguilarIBCabrera-QuinteroAJZentella-DehesaAGenomic and non-genomic effects of glucocorticoids: implications for breast cancerInt J Clin Exp Pathol20158111025755688
   PubMed Web of Science ®Google Scholar
• VilascoMCommunalLHugon-RodinJLoss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissueBreast Cancer Res Treat2013142228329624166279
   PubMed Web of Science ®Google Scholar
• ReederAAttarMNazarioLStress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damageBr J Cancer201511291461147025880007
   PubMed Web of Science ®Google Scholar
• SkorMNWonderELKocherginskyMGoyalAHallBACaiYConzenSDGlucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancerClin Cancer Res201319226163617224016618
   PubMed Web of Science ®Google Scholar
• AntonovaLMuellerCRHydrocortisone down-regulates the tumor suppressor gene BRCA1 in mammary cells: a possible molecular link between stress and breast cancerGenes Chromosomes Cancer200847434135218196591
   PubMed Web of Science ®Google Scholar
• RitterHDAntonovaLMuellerCRThe unliganded glucocorticoid receptor positively regulates the tumor suppressor gene BRCA1 through GABP betaMol Cancer Res201210455856922328717
   PubMed Web of Science ®Google Scholar
• BirchJMAlstonRDMcNallyRJRelative frequency and morphology of cancers in carriers of germline TP53 mutationsOncogene200120344621462811498785
   PubMed Web of Science ®Google Scholar
• KimYKimJLeeHDJeongJLeeWLeeKASpectrum of EGFR gene copy number changes and KRAS gene mutation status in korean triple negative breast cancer patientsPLoS One2013810e7901424205362
   PubMed Web of Science ®Google Scholar
• KimJYParkKJungHHAssociation between mutation and expression of TP53 as a potential prognostic marker of triple-negative breast cancerCancer Res Treat Epub2016218
   Web of Science ®Google Scholar
• ÇakırTKhatibipourMJMetabolic network discovery by top-down and bottom-up approaches and paths for reconciliationFront Bioeng Biotechnol201426225520953
   PubMedGoogle Scholar
• DeanSJPerksCMHollyJMLoss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancerAm J Clin Pathol2014141332333324515759
   PubMed Web of Science ®Google Scholar